Literature DB >> 9824390

Comparison between eosinophilic markers in induced sputum and blood in asthmatic patients.

E Bacci1, S Cianchetti, L Ruocco, M L Bartoli, S Carnevali, F L Dente, A Di Franco, D Giannini, P Macchioni, B Vagaggini, M C Morelli, P L Paggiaro.   

Abstract

BACKGROUND: The usefulness and safety of the analysis of blood inflammatory markers in asthma are widely recognized. Recently, the analysis of induced sputum has been proposed as a safe, non-invasive tool in the study of airway inflammation in asthma.
OBJECTIVE: Our aim was to test whether sputum analysis is more useful than blood analysis in the evaluation of airway inflammation in untreated and treated asthmatic patients.
METHODS: Twelve untreated patients with mild to moderate asthma underwent a methacholine challenge test, sputum induction and blood sampling. A group of 14 normal subjects was also evaluated for baseline comparison. The same evaluation was repeated after 3 months of budesonide treatment. Before and after treatment, we tested the relationship of eosinophilic markers in induced sputum and blood with clinical and functional data. We also compared eosinophilic markers in induced sputum with the same markers in blood.
RESULTS: Untreated patients showed a significant relationship between sputum eosinophils and symptom score, and between sputum eosinophilic cationic protein and symptom score, FEV1 and PD20FEV1. No relationship between blood eosinophilic markers and clinical or functional data was observed. In budesonide-treated patients, both sputum and blood eosinophils were significantly lower than in untreated patients, but eosinophil decrease was greater in sputum than in blood. Sputum eosinophilic proteins were also significantly lower in treated patients, whereas serum eosinophilic proteins were low at baseline and remained unchanged after treatment. Sputum eosinophilic markers were lower in normal subjects than in both untreated and treated patients, while blood eosinophils, but not serum eosinophilic cationic protein, were lower in normals than in untreated patients.
CONCLUSIONS: The analysis of induced sputum is more useful than the analysis of blood in the evaluation of asthma severity and of the effect of glucocorticoid treatment in patients with mild to moderate asthma.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9824390     DOI: 10.1046/j.1365-2222.1998.00341.x

Source DB:  PubMed          Journal:  Clin Exp Allergy        ISSN: 0954-7894            Impact factor:   5.018


  5 in total

Review 1.  Budesonide inhalation suspension: a review of its use in infants, children and adults with inflammatory respiratory disorders.

Authors:  K M Hvizdos; B Jarvis
Journal:  Drugs       Date:  2000-11       Impact factor: 9.546

2.  Effectiveness of inhaled corticosteroids in real life on clinical outcomes, sputum cells and systemic inflammation in asthmatics: a retrospective cohort study in a secondary care centre.

Authors:  Sophie F Demarche; Florence N Schleich; Monique A Henket; Virginie A Paulus; Thierry J Van Hees; Renaud E Louis
Journal:  BMJ Open       Date:  2017-11-28       Impact factor: 2.692

3.  Understanding asthma phenotypes: the World Asthma Phenotypes (WASP) international collaboration.

Authors:  Lucy Pembrey; Mauricio L Barreto; Jeroen Douwes; Philip Cooper; John Henderson; Harriet Mpairwe; Cristina Ardura-Garcia; Martha Chico; Collin Brooks; Alvaro A Cruz; Alison M Elliott; Camila A Figueiredo; Sinéad M Langan; Beatrice Nassanga; Susan Ring; Laura Rodrigues; Neil Pearce
Journal:  ERJ Open Res       Date:  2018-08-22

Review 4.  Blood Eosinophils as Biomarkers to Drive Treatment Choices in Asthma and COPD.

Authors:  Konstantinos Kostikas; Caterina Brindicci; Francesco Patalano
Journal:  Curr Drug Targets       Date:  2018       Impact factor: 3.465

5.  The predictive value of eosinophil cationic protein and lactate dehydrogenase in asthma: a comparative study of serum versus sputum.

Authors:  Amina Hamed Ahmad Al Obaidi; Abdul Ghani Mohamed Al Samarai; Jasim Al-Janabi; Abdulkareem Yahia
Journal:  World Allergy Organ J       Date:  2009-07       Impact factor: 4.084

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.